Fragile X study uncovers brainwave biomarker bridging humans and mice

Numerous potential treatments for neurological conditions, including autism spectrum disorders, have worked well in lab mice but then disappointed in humans. What would help is a noninvasive, objective readout of treatment efficacy that is shared in both species. In a new study in Nature Communications, a team of MIT researchers backed by collaborators across the United States and in the United Kingdom identifies such a biomarker in fragile X syndrome, the most common inherited autism form.